In 2006, ATryn® became the first transgenically produced therapeutic protein to be approved anywhere in the world when GTC obtained the European Commission’s approval of the use of ATryn® as a prophylactic treatment for patients with hereditary antithrombin deficiency, or HD, undergoing surgical procedures. On February 6, 2009, GTC received United States Food and Drug Administration, or FDA, approval for ATryn® for HD patients undergoing surgery or childbirth in the United States, making ATryn® the first transgenically derived therapeutic protein approved by the FDA.

GTC Biotherapeutics is developing transgenic versions of therapeutic proteins to treat unmet medical needs and chronic illnesses that are currently being produced in cell culture or extracted from human plasma, as well as novel proteins that cannot be produced using traditional methods. For a listing of development activities, please view the Products and Partnering section of this web site.

GTC Biotherapeutics contracts with biotechnology and pharmaceutical companies to produce transgenic versions of drugs under development by these companies using our transgenic technology for which GTC would receive revenue, royalties, and possibly, marketing rights to the resulting product. GTC Biotherapeutics also has its own protein portfolio of drug candidates under development which are available for external corporate partnering. During the development of a program, GTC receives revenue from a partner based on completing project milestones.

The company's burn rate depends upon operating costs and expenses as well as the contract revenue and milestone payments received from its customers. Since the timing of revenue and milestone payments are dependent upon numerous factors, providing an estimated burn rate is difficult and is updated during GTC's quarterly conference call with financial analysts. A recording of the latest call is available on this website.

For 2008, the fiscal year ended December 28, 2008.

The financial results will typically be released approximately 5 weeks after the end of a quarter. The specific date will be announced about one week ahead of the distribution of the press release describing the results. This press release is usually distributed before the market opens and a conference call is held later that same day, generally at 10:00 a.m. Eastern time.

No, the company does not have a direct stock purchase plan.

GTC Biotherapeutics has never paid a cash dividend on its common stock, and currently expects that future earnings will be retained for use in its business.

The transfer agent for GTC Biotherapeutics is:
American Stock Transfer & Trust Company
40 Wall Street, 46th Floor
New York, NY 10005
Telephone: 1-800-937-5449

GTC Biotherapeutics is a stand-alone public company traded on the Nasdaq National Market System. In July 1993, Genzyme Transgenics was organized as a separate business, distinct from Genzyme Corporation, in order to fully realize the potential value of producing therapeutic proteins in the milk of transgenic animals. On June 3, 2002, Genzyme Transgenics became GTC Biotherapeutics in order to bring clarity to its identity and independence while highlighting the familiar initials by which it was already known.

No, GTC Biotherapeutics is not a tracking stock of Genzyme Corporation, but is a separate corporation, with a separate board of directors. The assets of GTC Biotherapeutics are held by its shareholders, and the Company has separate and distinct business goals and objectives from that of Genzyme Corporation.

Our stock symbol is GTCB, which is traded on The NASDAQ Capital Market.

GTC Biotherapeutics produces human therapeutic proteins in the milk of transgenic animals. GTC is developing monoclonal antibodies, plasma proteins, and other novel proteins that may be potential treatments for a wide variety of human illnesses, such as autoimmune disorders and cancer.

As of December 28, 2008, GTC Biotherapeutics employed 159 people.

Go to About GTC Biotherapeutics Section

• Geoffrey F. Cox, Ph.D., Chairman, President and CEO, GTC Biotherapeutics, Inc.
• Christian Béchon, Chairman and CEO, LFB Biotechnologies
• Francis J. Bullock, Ph.D., Independent Consultant, former Sr. Vice President of Research Operations, Schering-Plough Pharmaceutical Research Institute
• James A. Geraghty, Senior Vice President, Genzyme Corporation
• William Heiden, Outside Director, LFB Biotechnologies and Managing Director of Vitruvian Pharmaceuticals
• Michael J. Landine, Senior Vice President Corporate Development, Alkermes, Inc.
• Pamela W. McNamara, President, Cambridge Consultants, Inc. former CEO, CRF, Inc., Arthur D. Little
• Bertrand Merot, Ph.D., Chief Operating Officer, LFB Biotechnologies
• Evelyne Nguyen, Director of Financial Affairs and Strategy, LFB S.A.
• Jean-François Prost M.D., Chief Medical and Scientific Officer, LFB Biotechnologies S.A.
• Alan W. Tuck, Partner, Bridgespan Group, a nonprofit consulting organization

The annual meeting was held Wednesday, May 27, 2009 at 2:00 pm.